GlaxoSmithKline PLC

Landmark IMPACT study to be published in NEJM

RNS Number : 3186L
GlaxoSmithKline PLC
18 April 2018
 

 

Issued: 18 April 2018, London UK - LSE Announcement

 

Landmark IMPACT study to be published in NEJM

 

 

 

GlaxoSmithKline plc (LSE/NYSE: GSK) will today announce at 22:00 BST its IMPACT data.

 

 

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com. 

 

 

GSK enquiries:




UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502

(London)


David Daley

+44 (0) 20 8047 5502

(London)





Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194

(London)


Tom Curry

+ 1 215 751 5419

(Philadelphia)


James Dodwell

+44 (0) 20 8047 2406

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)





 

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKVLBFVZFXBBF